Raffaele Pellegrino

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Ulcerative Colitis

Helicobacter Pylori

Disease Activity

Top Venues

Diseases (Basel, Switzerland)

International journal of molecular sciences

Expert review of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate? Diseases (Basel, Switzerland) 12 (8) (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate? Diseases (Basel, Switzerland) 12 (8) (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Mario Romeo, Marina Cipullo, Stefano Lucà, Iacopo Panarese, Alessandro Federico
Vanek's Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report. Reviews on recent clinical trials (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Veronica Iascone, Giovanna Palladino, Alessandro Federico, Rocco Maurizio Zagari
Impact of Helicobacter pylori Eradication on Inflammatory Bowel Disease Onset and Disease Activity: To Eradicate or Not to Eradicate? Diseases (Basel, Switzerland) 12 (8) (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers 16 (3) (2024)
Pilar Chacon-Millan, Stefania Lama, Nunzio Del Gaudio, Antonietta Gerarda Gravina, Alessandro Federico, Raffaele Pellegrino, Amalia Luce, Lucia Altucci, Angelo Facchiano, Michele Caraglia, Paola Stiuso
A Combination of Microarray-Based Profiling and Biocomputational Analysis Identified miR331-3p and hsa-let-7d-5p as Potential Biomarkers of Ulcerative Colitis Progression to Colorectal Cancer. International journal of molecular sciences 25 (11) (2024)
Pilar Chacon-Millan, Stefania Lama, Nunzio Del Gaudio, Antonietta Gerarda Gravina, Alessandro Federico, Raffaele Pellegrino, Amalia Luce, Lucia Altucci, Angelo Facchiano, Michele Caraglia, Paola Stiuso
A Combination of Microarray-Based Profiling and Biocomputational Analysis Identified miR331-3p and hsa-let-7d-5p as Potential Biomarkers of Ulcerative Colitis Progression to Colorectal Cancer. International journal of molecular sciences 25 (11) (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Alfonso Esposito, Marina Cipullo, Mario Romeo, Giovanna Palladino, Patrizia Iodice, Alessandro Federico, Teresa Troiani
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers 16 (3) (2024)
Pilar Chacon-Millan, Stefania Lama, Nunzio Del Gaudio, Antonietta Gerarda Gravina, Alessandro Federico, Raffaele Pellegrino, Amalia Luce, Lucia Altucci, Angelo Facchiano, Michele Caraglia, Paola Stiuso
A Combination of Microarray-Based Profiling and Biocomputational Analysis Identified miR331-3p and hsa-let-7d-5p as Potential Biomarkers of Ulcerative Colitis Progression to Colorectal Cancer. International journal of molecular sciences 25 (11) (2024)
Antonietta Gerarda Gravina, Raffaele Pellegrino, Tommaso Durante, Giovanna Palladino, Giuseppe Imperio, Giovanbattista D'Amico, Maria Consiglia Trotta, Marcello Dallio, Mario Romeo, Michele D'Amico, Alessandro Federico
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. Cells 12 (14) (2023)
Raffaele Pellegrino, Gianluca Pellino, Lucio Selvaggi, Francesco Selvaggi, Alessandro Federico, Marco Romano, Antonietta Gerarda Gravina
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study. Expert review of clinical pharmacology 15 (10) (2022)